Solvonis Therapeutics plc

Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder

SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product consists of SVN-114 for the treatment of post-traumatic stress disorder; and SVN-015 for the treatment of stimulant use disorder. Incorporated in 2017 and headquartered in London, the United Kingdom, Solvonis Therapeutics was formerly known as Graft Polymer (UK) Plc before rebranding in January 2025.